ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$162.86
+1.86%Year over year
Reported trailing growth
- Revenue
- +56.2%
- EBITDA
- +569.1%
- EBIT
- +269.3%
- EPS
- +6474.2%
- Free cash flow
- +126.2%
- Operating cash flow
- +144.6%
Forward estimates
Based on analyst estimates
- Revenue
- +28.8%
- EBITDA
- +14.6%
- EPS
- -65.5%
Three-year CAGR
- Revenue
- +53.0%
- EBITDA
- +453.1%
- EBIT
- +383.6%
- Net income
- +212.8%
- EPS
- +209.6%
- Free cash flow
- +233.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026